MiMedx Group (NASDAQ: MDXG) — Perfil da empresa, notícias e dados financeiros
MiMedx Group develops regenerative therapies using human placental tissue allografts, targeting inflammation and wounds.
MiMedx Group
MiMedx Group (NASDAQ:MDXG) is a healthcare company primarily focused on developing, manufacturing, and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare. The company's mission is to harness the power of placental tissue in regenerating damaged tissues, thus enhancing the body's own healing process. Through innovative research and development, MiMedx is dedicated to providing advanced treatment options for patients suffering from various conditions, including inflammation, wounds, and burns. Their projects aim to meet unmet clinical needs, offering solutions that improve patient outcomes and reduce overall healthcare costs. The overarching objective is to continue advancing in regenerative medicine by expanding their product portfolio and reach, thus significantly impacting lives across the globe.
Resumo
Operações
Produtos e/ou serviços de MiMedx Group
- EpiFix, a bioactive tissue matrix for promoting skin healing.
- AmnioFix, an allograft composed of dehydrated human amnion/chorion membrane for use in various surgical specialties.
- EpiCord, a dehydrated human umbilical cord allograft designed for wound management.
- AmnioFill, a placental collagen matrix that supports tissue regeneration in surgical applications.
- EpiBurn, a wound care product designed for burn healing and management.
- Purion Process, a proprietary method to clean, process, and preserve allograft tissues ensuring safety and efficacy.
equipe executiva do MiMedx Group
- Joseph H. CapperCEO & Director
- Douglas C. RiceChief Financial Officer
- William F. Hulse IVGeneral Counsel & Chief Administrative Officer
- Kimberly Maersk-MollerChief Commercial Officer
- John HarperSVP of R&D & Medical Affairs and Chief Scientific Officer
- Matthew M. NotarianniHead of Investor Relations
- Mark P. GravesSenior VP & Chief Compliance Officer
- Hilary DixonVice President of Investor Relations & Corporate Strategic Communications
- Eric A. SmithSenior VP of Marketing & International
- Tracy ChastainChief Human Resources Officer
Principais indicadores financeiros
Resultados divulgados pela MiMedx Group, em USD.
- Cap. de mercado
- 576,4 mi
- Receita (TTM)
- 355,2 mi
- P/L
- 98.8
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 1.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 418,6 mi | 63,9 mi | 48,6 mi | |
| 348,9 mi | 58,9 mi | 42,4 mi | |
| 321,5 mi | 37,1 mi | 67,4 mi | |
| 267,8 mi | -14,7 mi | -30,2 mi |